The FDA drug approval process: from phase III to pharmacy
The path a drug travels from a laboratory bench to a pharmacy shelf is long, expensive, and heavily regulated. The FDA describes it as a five-step process: discovery and development, preclinical research, clinical research, FDA review, and post-market safety monitoring (FDA drug development process). Most people only ever hear about the middle part, the clinical trials where a drug is tested on people. That is the stage that decides whether a compound with promising lab results becomes a medicine you can actually buy.
Before phase III: the groundwork
Before any human is exposed to a new drug, the developer has to show it is worth testing at all. Discovery happens in the laboratory, where researchers identify a molecule and study how it behaves. Preclinical research then moves to laboratory and animal testing to answer basic questions about safety: what the drug does to the body, how the body processes it, and what dose looks tolerable. Only if those studies look reasonable does a company file an investigational new drug application (IND) with the FDA, requesting permission to begin testing in humans (FDA IND forms and instructions).
What phase III actually is
Clinical research in the US is typically described in three phases. Phase I trials enroll a small number of people, often healthy volunteers, to study safety and dosing. Phase II trials use a larger group of patients to look for signs the drug works and to refine the dose. Phase III trials are the big ones: large studies in the patient population the drug is intended for, designed to confirm that the treatment is safe and effective compared with standard care or placebo.
Phase III is where the evidence that matters for approval gets made. These trials can enroll thousands of patients at sites around the world and run for years. The results of phase III studies form the core of the package a company submits to the FDA when it asks for permission to market the drug. ClinicalTrials.gov, the registry run by the US National Institutes of Health, maintains a public record of these trials, including their purpose, design, and results (ClinicalTrials.gov). That registry is a reminder that phase III does not happen in a vacuum: every step is documented, and much of it is public.
The New Drug Application
If the phase III results show the drug is safe and effective for its intended use, the developer files a New Drug Application, or NDA, with the FDA. The NDA is meant to tell the full story of the drug. It must include everything: preclinical data, all clinical trial reports, proposed labeling, safety updates, drug abuse information, patent information, and data from studies conducted outside the United States (FDA step 4: FDA drug review).
Once the FDA receives the NDA, a review team decides whether the application is complete enough to file. If it is not, the agency can refuse to file it, sending the developer back to fill the gaps. If it is complete, the review team has six to ten months to make a decision on whether to approve the drug.
What happens during FDA review
The review itself is a team effort. Each member of the review team examines their own section of the application: the medical officer and the statistician review the clinical data, a pharmacologist reviews the animal study data, and supervisors review the work within each discipline. FDA inspectors travel to clinical study sites to conduct routine inspections, looking for evidence of fabrication, manipulation, or withholding of data. The project manager then assembles all the individual reviews, the inspection report, and related documents into an action package that becomes the record for the decision.
Sometimes the application raises questions that need extra consideration. In those cases the FDA may convene one of its advisory committees, independent experts who give advice and hear public comment, including from a patient representative. Advisory committees do not make the final call; the agency does. But their input is part of the record.
If the FDA determines the drug has been shown to be safe and effective for its intended use, the agency works with the developer to refine the prescribing information, the labeling that describes how to use the drug. Often remaining issues must be resolved first. Sometimes the developer must answer questions based on existing data; sometimes additional studies are required. A developer who disagrees with an FDA decision has formal mechanisms for appeal.
After approval: the pharmacy and beyond
Approval is not the end of the road. Once a drug is on the market, the FDA continues to monitor its safety in the general population, where far more people may be exposed than in any trial (FDA drug development process). Phase IV studies, conducted after approval, can answer questions about long-term safety, rare side effects, and use in broader or different populations. Reports of problems from patients and health professionals feed into this monitoring, and the agency can act if new safety signals emerge.
Getting a drug to the pharmacy also involves paperwork that shapes the whole industry. The FDA's Center for Drug Evaluation and Research publishes the forms and reporting requirements that sponsors, investigators, and sites must use throughout development and after approval, from IND submissions to post-market reports (FDA CDER forms and reports). For anyone working in clinical research, those forms are as familiar as the trials themselves.
The bottom line
The trip from phase III to pharmacy runs through one place: the NDA review. Phase III supplies the evidence, the NDA packages it, and the FDA review team decides whether it holds up. Approval takes six to ten months of review after years of development, and it comes with continued safety monitoring for as long as the drug is on the market. Understanding that process matters for patients, who can ask better questions about the medicines they take, and for researchers, who design the trials that feed it.
This article is based on the Clarity Clinical Solutions video "FDA Drug Approval Process Explained: From Phase III to Pharmacy." Watch it here: FDA Drug Approval Process Explained: From Phase III to Pharmacy
References
- Clarity Clinical Solutions — "FDA Drug Approval Process Explained: From Phase III to Pharmacy" (source video). https://www.youtube.com/watch?v=w64pD4-Xam4
- FDA — The Drug Development Process (five-step overview). https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process
- FDA — Step 4: FDA Drug Review (NDA content, review timeline, inspections, advisory committees). https://www.fda.gov/patients/drug-development-process/step-4-fda-drug-review
- FDA — IND Forms and Instructions. https://www.fda.gov/drugs/investigational-new-drug-ind-application/ind-forms-and-instructions
- FDA — CDER Forms and Reports. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/forms-reports
- ClinicalTrials.gov — Public registry of clinical studies. https://clinicaltrials.gov/